Medical Care
Global Castrate Resistant Prostate Cancer Therapeutics Market Research Report 2025
- Mar 13, 25
- ID: 130505
- Pages: 78
- Figures: 80
- Views: 25
The global market for Castrate Resistant Prostate Cancer Therapeutics was valued at US$ 18800 million in the year 2024 and is projected to reach a revised size of US$ 39170 million by 2031, growing at a CAGR of 11.2% during the forecast period.
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.
Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.
This report aims to provide a comprehensive presentation of the global market for Castrate Resistant Prostate Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castrate Resistant Prostate Cancer Therapeutics.
The Castrate Resistant Prostate Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Castrate Resistant Prostate Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castrate Resistant Prostate Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Segment by Type
Hormonal Therapy
Chemotherapy
Others
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castrate Resistant Prostate Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.
Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.
This report aims to provide a comprehensive presentation of the global market for Castrate Resistant Prostate Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castrate Resistant Prostate Cancer Therapeutics.
The Castrate Resistant Prostate Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Castrate Resistant Prostate Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castrate Resistant Prostate Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Segment by Type
Hormonal Therapy
Chemotherapy
Others
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castrate Resistant Prostate Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hormonal Therapy
1.2.3 Chemotherapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Perspective (2020-2031)
2.2 Global Castrate Resistant Prostate Cancer Therapeutics Growth Trends by Region
2.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Castrate Resistant Prostate Cancer Therapeutics Market Dynamics
2.3.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends
2.3.2 Castrate Resistant Prostate Cancer Therapeutics Market Drivers
2.3.3 Castrate Resistant Prostate Cancer Therapeutics Market Challenges
2.3.4 Castrate Resistant Prostate Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue
3.1.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Castrate Resistant Prostate Cancer Therapeutics Revenue
3.4 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2024
3.5 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics Head office and Area Served
3.6 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Product and Application
3.7 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Type
4.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2026-2031)
5 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Application
5.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
6.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025)
6.4 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
7.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025)
7.4 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
9.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer/Astellas (Xtandi)
11.1.1 Pfizer/Astellas (Xtandi) Company Details
11.1.2 Pfizer/Astellas (Xtandi) Business Overview
11.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Introduction
11.1.4 Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.1.5 Pfizer/Astellas (Xtandi) Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Introduction
11.2.4 Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.2.5 Johnson & Johnson Recent Development
11.3 AstraZeneca/Merck (Lynparza)
11.3.1 AstraZeneca/Merck (Lynparza) Company Details
11.3.2 AstraZeneca/Merck (Lynparza) Business Overview
11.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Introduction
11.3.4 AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.3.5 AstraZeneca/Merck (Lynparza) Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Introduction
11.4.4 Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.4.5 Bayer Recent Development
11.5 Jiangsu Hengrui Pharmaceuticals
11.5.1 Jiangsu Hengrui Pharmaceuticals Company Details
11.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Introduction
11.5.4 Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.5.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.6 CTTQ
11.6.1 CTTQ Company Details
11.6.2 CTTQ Business Overview
11.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Introduction
11.6.4 CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.6.5 CTTQ Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Introduction
11.7.4 Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.7.5 Sanofi Recent Development
11.8 Hansoh
11.8.1 Hansoh Company Details
11.8.2 Hansoh Business Overview
11.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Introduction
11.8.4 Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.8.5 Hansoh Recent Development
11.9 Clovis Oncology
11.9.1 Clovis Oncology Company Details
11.9.2 Clovis Oncology Business Overview
11.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Introduction
11.9.4 Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.9.5 Clovis Oncology Recent Development
11.10 Zhendong Pharmaceutical
11.10.1 Zhendong Pharmaceutical Company Details
11.10.2 Zhendong Pharmaceutical Business Overview
11.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Introduction
11.10.4 Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.10.5 Zhendong Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hormonal Therapy
1.2.3 Chemotherapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Perspective (2020-2031)
2.2 Global Castrate Resistant Prostate Cancer Therapeutics Growth Trends by Region
2.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Castrate Resistant Prostate Cancer Therapeutics Market Dynamics
2.3.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends
2.3.2 Castrate Resistant Prostate Cancer Therapeutics Market Drivers
2.3.3 Castrate Resistant Prostate Cancer Therapeutics Market Challenges
2.3.4 Castrate Resistant Prostate Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue
3.1.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Castrate Resistant Prostate Cancer Therapeutics Revenue
3.4 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2024
3.5 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics Head office and Area Served
3.6 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Product and Application
3.7 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Type
4.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2026-2031)
5 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Application
5.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
6.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025)
6.4 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
7.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025)
7.4 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
9.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer/Astellas (Xtandi)
11.1.1 Pfizer/Astellas (Xtandi) Company Details
11.1.2 Pfizer/Astellas (Xtandi) Business Overview
11.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Introduction
11.1.4 Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.1.5 Pfizer/Astellas (Xtandi) Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Introduction
11.2.4 Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.2.5 Johnson & Johnson Recent Development
11.3 AstraZeneca/Merck (Lynparza)
11.3.1 AstraZeneca/Merck (Lynparza) Company Details
11.3.2 AstraZeneca/Merck (Lynparza) Business Overview
11.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Introduction
11.3.4 AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.3.5 AstraZeneca/Merck (Lynparza) Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Introduction
11.4.4 Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.4.5 Bayer Recent Development
11.5 Jiangsu Hengrui Pharmaceuticals
11.5.1 Jiangsu Hengrui Pharmaceuticals Company Details
11.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Introduction
11.5.4 Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.5.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.6 CTTQ
11.6.1 CTTQ Company Details
11.6.2 CTTQ Business Overview
11.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Introduction
11.6.4 CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.6.5 CTTQ Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Introduction
11.7.4 Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.7.5 Sanofi Recent Development
11.8 Hansoh
11.8.1 Hansoh Company Details
11.8.2 Hansoh Business Overview
11.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Introduction
11.8.4 Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.8.5 Hansoh Recent Development
11.9 Clovis Oncology
11.9.1 Clovis Oncology Company Details
11.9.2 Clovis Oncology Business Overview
11.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Introduction
11.9.4 Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.9.5 Clovis Oncology Recent Development
11.10 Zhendong Pharmaceutical
11.10.1 Zhendong Pharmaceutical Company Details
11.10.2 Zhendong Pharmaceutical Business Overview
11.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Introduction
11.10.4 Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
11.10.5 Zhendong Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Hormonal Therapy
Table 3. Key Players of Chemotherapy
Table 4. Key Players of Others
Table 5. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2020-2025)
Table 9. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2026-2031)
Table 11. Castrate Resistant Prostate Cancer Therapeutics Market Trends
Table 12. Castrate Resistant Prostate Cancer Therapeutics Market Drivers
Table 13. Castrate Resistant Prostate Cancer Therapeutics Market Challenges
Table 14. Castrate Resistant Prostate Cancer Therapeutics Market Restraints
Table 15. Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players (2020-2025)
Table 17. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2024)
Table 18. Ranking of Global Top Castrate Resistant Prostate Cancer Therapeutics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Product and Application
Table 22. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2020-2025)
Table 26. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2026-2031)
Table 28. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2020-2025)
Table 30. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2026-2031)
Table 32. North America Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Pfizer/Astellas (Xtandi) Company Details
Table 48. Pfizer/Astellas (Xtandi) Business Overview
Table 49. Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product
Table 50. Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 51. Pfizer/Astellas (Xtandi) Recent Development
Table 52. Johnson & Johnson Company Details
Table 53. Johnson & Johnson Business Overview
Table 54. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product
Table 55. Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 56. Johnson & Johnson Recent Development
Table 57. AstraZeneca/Merck (Lynparza) Company Details
Table 58. AstraZeneca/Merck (Lynparza) Business Overview
Table 59. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product
Table 60. AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 61. AstraZeneca/Merck (Lynparza) Recent Development
Table 62. Bayer Company Details
Table 63. Bayer Business Overview
Table 64. Bayer Castrate Resistant Prostate Cancer Therapeutics Product
Table 65. Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Bayer Recent Development
Table 67. Jiangsu Hengrui Pharmaceuticals Company Details
Table 68. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 69. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product
Table 70. Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 72. CTTQ Company Details
Table 73. CTTQ Business Overview
Table 74. CTTQ Castrate Resistant Prostate Cancer Therapeutics Product
Table 75. CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 76. CTTQ Recent Development
Table 77. Sanofi Company Details
Table 78. Sanofi Business Overview
Table 79. Sanofi Castrate Resistant Prostate Cancer Therapeutics Product
Table 80. Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 81. Sanofi Recent Development
Table 82. Hansoh Company Details
Table 83. Hansoh Business Overview
Table 84. Hansoh Castrate Resistant Prostate Cancer Therapeutics Product
Table 85. Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 86. Hansoh Recent Development
Table 87. Clovis Oncology Company Details
Table 88. Clovis Oncology Business Overview
Table 89. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Product
Table 90. Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 91. Clovis Oncology Recent Development
Table 92. Zhendong Pharmaceutical Company Details
Table 93. Zhendong Pharmaceutical Business Overview
Table 94. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product
Table 95. Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 96. Zhendong Pharmaceutical Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
Table 100. Authors List of This Report
List of Figures
Figure 1. Castrate Resistant Prostate Cancer Therapeutics Picture
Figure 2. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Hormonal Therapy Features
Figure 5. Chemotherapy Features
Figure 6. Others Features
Figure 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Specialty Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Castrate Resistant Prostate Cancer Therapeutics Report Years Considered
Figure 13. Global Castrate Resistant Prostate Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Castrate Resistant Prostate Cancer Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region: 2024 VS 2031
Figure 16. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players in 2024
Figure 17. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2024
Figure 19. North America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2020-2031)
Figure 21. United States Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2020-2031)
Figure 25. Germany Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2020-2031)
Figure 33. China Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2020-2031)
Figure 41. Mexico Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2020-2031)
Figure 45. Turkey Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Pfizer/Astellas (Xtandi) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 49. Johnson & Johnson Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 50. AstraZeneca/Merck (Lynparza) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 51. Bayer Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 52. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 53. CTTQ Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 54. Sanofi Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 55. Hansoh Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 56. Clovis Oncology Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 57. Zhendong Pharmaceutical Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Table 1. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Hormonal Therapy
Table 3. Key Players of Chemotherapy
Table 4. Key Players of Others
Table 5. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2020-2025)
Table 9. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2026-2031)
Table 11. Castrate Resistant Prostate Cancer Therapeutics Market Trends
Table 12. Castrate Resistant Prostate Cancer Therapeutics Market Drivers
Table 13. Castrate Resistant Prostate Cancer Therapeutics Market Challenges
Table 14. Castrate Resistant Prostate Cancer Therapeutics Market Restraints
Table 15. Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players (2020-2025)
Table 17. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2024)
Table 18. Ranking of Global Top Castrate Resistant Prostate Cancer Therapeutics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Product and Application
Table 22. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2020-2025)
Table 26. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2026-2031)
Table 28. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2020-2025)
Table 30. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2026-2031)
Table 32. North America Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Pfizer/Astellas (Xtandi) Company Details
Table 48. Pfizer/Astellas (Xtandi) Business Overview
Table 49. Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product
Table 50. Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 51. Pfizer/Astellas (Xtandi) Recent Development
Table 52. Johnson & Johnson Company Details
Table 53. Johnson & Johnson Business Overview
Table 54. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product
Table 55. Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 56. Johnson & Johnson Recent Development
Table 57. AstraZeneca/Merck (Lynparza) Company Details
Table 58. AstraZeneca/Merck (Lynparza) Business Overview
Table 59. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product
Table 60. AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 61. AstraZeneca/Merck (Lynparza) Recent Development
Table 62. Bayer Company Details
Table 63. Bayer Business Overview
Table 64. Bayer Castrate Resistant Prostate Cancer Therapeutics Product
Table 65. Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Bayer Recent Development
Table 67. Jiangsu Hengrui Pharmaceuticals Company Details
Table 68. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 69. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product
Table 70. Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 72. CTTQ Company Details
Table 73. CTTQ Business Overview
Table 74. CTTQ Castrate Resistant Prostate Cancer Therapeutics Product
Table 75. CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 76. CTTQ Recent Development
Table 77. Sanofi Company Details
Table 78. Sanofi Business Overview
Table 79. Sanofi Castrate Resistant Prostate Cancer Therapeutics Product
Table 80. Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 81. Sanofi Recent Development
Table 82. Hansoh Company Details
Table 83. Hansoh Business Overview
Table 84. Hansoh Castrate Resistant Prostate Cancer Therapeutics Product
Table 85. Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 86. Hansoh Recent Development
Table 87. Clovis Oncology Company Details
Table 88. Clovis Oncology Business Overview
Table 89. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Product
Table 90. Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 91. Clovis Oncology Recent Development
Table 92. Zhendong Pharmaceutical Company Details
Table 93. Zhendong Pharmaceutical Business Overview
Table 94. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product
Table 95. Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 96. Zhendong Pharmaceutical Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
Table 100. Authors List of This Report
List of Figures
Figure 1. Castrate Resistant Prostate Cancer Therapeutics Picture
Figure 2. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Hormonal Therapy Features
Figure 5. Chemotherapy Features
Figure 6. Others Features
Figure 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Specialty Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Castrate Resistant Prostate Cancer Therapeutics Report Years Considered
Figure 13. Global Castrate Resistant Prostate Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Castrate Resistant Prostate Cancer Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region: 2024 VS 2031
Figure 16. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players in 2024
Figure 17. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2024
Figure 19. North America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2020-2031)
Figure 21. United States Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2020-2031)
Figure 25. Germany Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2020-2031)
Figure 33. China Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2020-2031)
Figure 41. Mexico Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2020-2031)
Figure 45. Turkey Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Pfizer/Astellas (Xtandi) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 49. Johnson & Johnson Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 50. AstraZeneca/Merck (Lynparza) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 51. Bayer Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 52. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 53. CTTQ Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 54. Sanofi Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 55. Hansoh Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 56. Clovis Oncology Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 57. Zhendong Pharmaceutical Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232